Core Points - Regentis Biomaterials Ltd. has announced the pricing of its initial public offering (IPO) of 1,250,000 ordinary shares at $8.00 per share, aiming for gross proceeds of $10 million before expenses [1][3] - The ordinary shares are set to begin trading on the NYSE American under the symbol "RGNT" on December 4, 2025, with the offering expected to close around December 5, 2025 [2] - The company plans to utilize the net proceeds primarily for development activities, including completing its pivotal trial and preparing for PMA submission for its product GerlinC, as well as for corporate purposes such as debt repayment [3] Company Overview - Regentis Biomaterials Ltd. focuses on regenerative medicine, specifically developing innovative tissue repair solutions to enhance patient health and quality of life [6] - The company's lead product, GelrinC, is a cell-free hydrogel designed for treating articular knee cartilage injuries and has received CE mark approval in Europe [6] - Regentis aims to commercialize GelrinC in Europe while also working towards obtaining FDA approval in the United States [6]
Regentis Biomaterials Ltd. Announces Pricing of Initial Public Offering